Metropolis HealthcareNSE:METROPOLIS +1.41%95 Operating Margin % is 16.35% as of Mar. 2026, which is 26% below its 10-year median of 22.12. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 95/100 and a GF Value™ of ₹588.25 (Fairly Valued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 81.37% on this metric.
Metropolis Healthcare Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -9.8%.
The historical rank and industry rank for Metropolis Healthcare's Operating Margin % or its related term are showing as below:
NSE:METROPOLIS'
s Operating Margin % Range Over the Past 10 Years
Min: 14.6 Med: 22.12 Max: 25.77
Current: 16.23
NSE:METROPOLIS's Operating Margin % is ranked better than 81.37% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.32
vs NSE:METROPOLIS: 16.23
Metropolis Healthcare's 5-Year Average Operating Margin % Growth Rate was -9.80% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Metropolis Healthcare Operating Margin % Related Terms
Metropolis Healthcare Operating Margin % Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Metropolis Healthcare's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metropolis Healthcare (NSE:METROPOLIS) has a Operating Margin % of 16.35% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Metropolis Healthcare and its competitors. This is 26% below median its historical median of 22.12. Over the past decade, Metropolis Healthcare's Operating Margin % has ranged from 14.60 to 25.77. According to the industry distribution chart, Metropolis Healthcare ranks #38 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 18.6%.
Is Metropolis Healthcare's Operating Margin % too high?
Metropolis Healthcare's current Operating Margin % of 16.35% is 26% below median its 10-year median of 22.12. Over the past 10 years, this metric has ranged from a low of 14.60 to a high of 25.77. Based on the distribution chart, Metropolis Healthcare ranks #38 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #38 out of 204 companies for Operating Margin %. This places Metropolis Healthcare in the top 19% of its industry — outperforming the majority of peers. Historically, Metropolis Healthcare's own Operating Margin % has ranged from 14.60 to 25.77 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Metropolis Healthcare and its competitors. Metropolis Healthcare's current Operating Margin % is 16.35%, which is 26% below median its own 10-year median of 22.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.25, compared to a current price of ₹567.95 — trading 3.5% below its estimated fair value. The current Operating Margin % is 16.35%, which is 26% below median its 10-year median of 22.12. Metropolis Healthcare's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current Operating Margin % is 16.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹567.95 is trading 3.5% below its estimated GF Value™ of ₹588.25.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
Operating Margin %: 16.35% (26% below median its 10-year median of 22.12)
GF Value™: ₹588.25 vs. price of ₹567.95 (3.5% below fair value)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
95GF Score
Get the complete analysis for NSE:METROPOLIS
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
